Health care startups in China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Hypershell | Shenzhen | Series B | $50.0M | 2026-05-18 |
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Tianhu Technology | Minhang | Series A | $29.0M | 2026-07-13 |
| Degron Therapeutics | Shanghai | Series A | $40.0M | 2026-05-14 |
| Weikaier Pharmaceutical Technology | Nanjing | Series C | $29.6M | 2026-06-02 |
| MindRank AI | Shanghai | Series B | $52.0M | 2026-07-08 |
| Hyperway Pharm | Chengdu | Series B | $14.9M | 2026-10-15 |
8 rows of the CSV in 5 of its 18 columns.
- The 3,459 health care startups in China have raised $57.8B in total.
- 525 of them closed their most recent round in the last 12 months, $7.0B combined.
- The largest of those rounds is CORXEL Pharmaceuticals' $287.0M Series D, dated January 2026.
- The most recent is Shanghai Peptide Biotechnology's $140K seed round on 10 November 2026.
- Qiming Venture Partners is an investor in 32 of them, more than any other fund.
- Biotech is the most common other sector, with 1,203 companies (35%).
- 26% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (39% of companies with a recorded size).
- 4 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 3,459| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Tushen Zhihe | Tushen Zhihe provides artificial intelligence protein design services. | Artificial intelligence | Minhang | Seed | $1.4M | 2026-11-09 | $1.5M | Wuxi Capital, CHENGMEI VENTURES | 11 to 50 | 2023 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Hyperway Pharm | Hyperway Pharm conducts pharmaceutical research, development, and production. | Health care | Chengdu | Series B | $14.9M | 2026-10-15 | $56.8M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, Huaige Capital +1 | 51 to 100 | 2019 |
| Aibo Medical Robot | Aibo Medical Robot researches and develops robots for vascular interventional surgery. | Hardware | Shenzhen | Series A | $14.1M | 2026-10-15 | $33.0M | Lenovo Capital and Incubator Group (LCIG), CDH Investments, Long Hill Capital +2 | 2020 | |
| Haimikang Intelligence | Haimikang Intelligence develops brain-computer interfaces and exoskeleton medical products. | Health care | Putuo | Seed | $1.4M | 2026-10-15 | $1.4M | New Access Capital | 51 to 100 | 2020 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Barty Medical | Barty Medical provides hospital healthcare services to patients. | Health care | Hangzhou | Series D | $29.5M | 2026-09-23 | $46.7M | Shenzhen Guozhong Venture Capital Management, Sinowisdom, Sunz Fund | 101 to 250 | 2015 |
| Nutshell Therapeutics | Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. | Artificial intelligence | Shanghai | Series C | $40.0M | 2026-09-15 | $75.2M | Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 | 51 to 100 | 2013 |
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Kossel Medical | Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. | Health care | Suzhou | Series C | $59.5M | 2026-09-01 | $103.0M | Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 | 501 to 1,000 | 2013 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| MileBot Robotics | MileBot Robotics develops robots for medical and healthcare applications. | Artificial intelligence | Shenzhen | Series B | $14.9M | 2026-08-26 | $14.9M | Lenovo Capital and Incubator Group (LCIG), Share Capital, Shangyuan Capital | 101 to 250 | 2016 |
| Leadinno Medical Valley | Leadinno Medical Valley produces medical devices that regulate neurological functions. | Health care | Beijing | Series B | $29.7M | 2026-08-17 | $90.3M | Fortune Venture Capital, Cowin Capital, Taiyu Investment +2 | 10,001 or more | 2016 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Phil Rivers Technology | Phil Rivers Technology provides AI solutions for pharmaceutical research and development. | Artificial intelligence | Beijing | Series A | $29.6M | 2026-08-05 | $57.3M | Insight Capital | 51 to 100 | 2015 |
| Kai Medtech | Kai Medtech markets and sells vascular intervention medical devices. | Health care | Minhang | Series D | $73.9M | 2026-07-28 | $105.3M | Shenzhen Capital Group, Wuxi Capital, Hengxu Capital +1 | 51 to 100 | 2019 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| Diyingjia Technology | Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. | Artificial intelligence | Beijing | Series C | $3.0M | 2026-07-28 | $32.3M | IDG Capital, Legend Capital, Microsoft Accelerator | 11 to 50 | 2017 |
| Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners, GSR United Capital, 3E Bioventures | 11 to 50 | 2021 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| Sonosemi Medical | Sonosemi Medical provides medical devices for vascular interventional diagnosis and treatment. | Health care | Shenzhen | Series B | $27.3M | 2026-07-08 | $27.3M | Eight Roads Ventures, Co-Stone Venture Capital, Guangzhou Yuexiu Industrial Investment Fund +1 | 101 to 250 | 2020 |
| Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Hangzhou | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. | Biotech | Shuangliu | Series A | $13.7M | 2026-06-26 | $13.7M | Legend Capital, Guosheng Capital, Firefly Haoyue | 11 to 50 | 2021 |
| Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
| Haimai Medical | Haimai Medical develops tissue engineering and regenerative medicine technologies. | Health care | Suzhou | Series A | $14.3M | 2026-06-12 | $14.3M | IDG Capital, Shanghai Biomedical Industrial Equity Investment Fund, Tahoe Venture +1 | 51 to 100 | 2021 |
Table 1. Health care startups in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 3,459.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| 3 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 4 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 5 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 6 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 7 | Surgerii Technology | Surgerii Technology develops minimally invasive surgical robots. | Hardware | Haidian | Series D | $100.0M | 2025-12-31 | $100.0M | Shunwei Capital, SDIC Venture Capital, Shanghai Biomedical Industrial Equity Investment Fund +1 | 11 to 50 | 2014 |
| 8 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| 9 | Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| 10 | MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
Table 2. Health care startups in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 32 | 1% | 8 | AusperBio, Tianhu Technology, Prime Lifescience |
| 2 | Matrix Partners China | Venture capital firm | Beijing, China | 23 | 1% | 3 | Nutshell Therapeutics, Alioth, D3 Bio |
| 3 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 21 | 1% | 3 | Kai Medtech, MoleculeMind, MAXVAX |
| 4 | IDG Capital | Private equity firm | Beijing, China | 20 | 1% | 6 | Layerwave Bio, Diyingjia Technology, Haimai Medical |
| 5 | BioVenture | Venture capital firm | Suzhou, China | 19 | 1% | 5 | AusperBio, Degron Therapeutics, AccuPulse |
| 6 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 16 | 0% | 2 | Aibo Medical Robot, HemaCell |
| 7 | Legend Capital | Venture capital firm | Beijing, China | 16 | 0% | 5 | Diyingjia Technology, Delova Biotech, Lingtai Krypton Biotechnology |
| 8 | Lenovo Capital and Incubator Group (LCIG) | Venture capital firm | Beijing, China | 14 | 0% | 4 | Aibo Medical Robot, MileBot Robotics, Zhonghe Gene |
| 9 | Puhua Capital | Venture capital firm | Hangzhou, China | 14 | 0% | 1 | Yuce Biotechnology |
| 10 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 13 | 0% | 3 | Nutshell Therapeutics, HemaCell, Jingwei Shida |
| 11 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 12 | 0% | 4 | Kossel Medical, Leadinno Medical Valley, RoboCT |
| 12 | ZhenFund | Entrepreneurship program | Beijing, China | 12 | 0% | ||
| 13 | Sherpa Healthcare Partners | Venture capital firm | Beijing, China | 11 | 0% | 1 | MindRank AI |
| 14 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 11 | 0% | 4 | Haimai Medical, AccuPulse, Surgerii Technology |
| 15 | Taiyu Investment | Venture capital firm | Beijing, China | 11 | 0% | 4 | Leadinno Medical Valley, Novamab, Tingsheng Technology |
Table 3. Health care startups in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 1,203 | 35% | $28.5B |
| Software | 417 | 12% | $6.7B |
| Hardware | 198 | 6% | $1.6B |
| Artificial intelligence | 183 | 5% | $3.7B |
| Commerce | 89 | 3% | $2.3B |
| Education | 57 | 2% | $233.3M |
| Fintech | 46 | 1% | $2.0B |
| Energy | 13 | 0% | $93.9M |
| Cybersecurity | 6 | 0% |
Table 4. Health care startups in China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Health care startups in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Health care startups in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 15 | 3% | $226.0M |
| October 2026 | 29 | 6% | $553.8M |
| September 2026 | 31 | 6% | $874.0M |
| August 2026 | 32 | 6% | $504.0M |
| July 2026 | 41 | 8% | $767.7M |
| June 2026 | 38 | 7% | $417.4M |
| May 2026 | 40 | 8% | $715.4M |
| April 2026 | 35 | 7% | $540.7M |
| March 2026 | 51 | 10% | $407.8M |
| February 2026 | 35 | 7% | $242.9M |
| January 2026 | 82 | 16% | $776.7M |
| December 2025 | 65 | 12% | $713.5M |
| November 2025 | 31 | 6% | $250.7M |
Table 7. Health care startups in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 429 | 12% | $6.0B |
| 2025 | 459 | 13% | $4.1B |
| 2024 | 305 | 9% | $2.0B |
| 2023 | 350 | 10% | $2.9B |
| 2022 | 262 | 8% | $3.8B |
| 2021 | 245 | 7% | $10.0B |
Table 8. Health care startups in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 246 | 7% |
| 2020 to 2022 | 638 | 19% |
| 2015 to 2019 | 1,250 | 37% |
| 2010 to 2014 | 793 | 23% |
| Before 2010 | 470 | 14% |
Table 9. Health care startups in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 265 | 10% |
| 11 to 50 | 1,062 | 39% |
| 51 to 100 | 543 | 20% |
| 101 to 250 | 426 | 16% |
| 251 to 500 | 214 | 8% |
| 501 to 1,000 | 100 | 4% |
| 1,001 to 5,000 | 72 | 3% |
| 5,001 to 10,000 | 9 | 0% |
| 10,001 or more | 10 | 0% |
Table 10. Health care startups in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its headquarters is in China. On 16 November 2026 that is 3,459 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 3,459 rows: 1,204 have no round amount, 0 no city and 1,328 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in China are on the list?
- 3,459, in the file dated 16 November 2026. 525 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 3,459 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.